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treatment PSA was 7.2 ng/ml (range, 0.8 to 19.9). The 
overall 3-year biochemical relapse free survival (bRFS) was 
93.9%. Cox regression identified primary gleason pattern as 
the only significant predictor of PSA relapse with a HR of 5.84 
(1.92 to 17.8, 95% CI) for primary gleason pattern 4 vs. 3. 
There was no significant difference in bRFS between patients 
classified as having favorable vs. unfavorable intermediate 
risk disease, HR 0.39 (0.11 to 1.41, 95% CI). There were no 
significant benefits observed with respect to ADT in any 
subgroup. 
 
Conclusion: Early PSA responses after SBRT for intermediate 
risk prostate adenocarcinoma compare favorably to those 
reported using other radiation therapy modalities. Primary 
gleason pattern 4 is predictive of less favorable bRFS, 
however early rates of PSA control are excellent compared to 
historical controls. The role of ADT in these patients is still 
unclear. The current evidence supports SBRT as a standard 
therapeutic option in intermediate risk disease. 
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Purpose or Objective: The aim of the study was to compare 
health-related quality of life (QoL) after external beam 
radiotherapy (RT) for prostate cancer with and without a 
hydrogel spacer. 
 
Material and Methods: A group of 202 patients with the 
indication for treatment of the prostate +/- base of seminal 
vesicles without pelvic lymph nodes was treated in a single 
institution in the years 2010-2013. Depending on the 
patient’s and responsible radiation oncologist’s preference, 
108 patients were selected for a hydrogel injection before 
the beginning of RT. The injection of 10 ml hydrogel was 
performed under transrectal ultrasound (TRUS) guidance 
after dissecting the space between prostate and rectum with 
a saline/lidocaine solution under local anaesthesia. 
Treatment was performed with a five-field IMRT or VMAT 
technique with daily ultrasound based image guidance. Only 
for patients with a spacer the prescription dose was 
increased from 76Gy to 78Gy, subsequently 80Gy. Patients 
were surveyed prospectively before RT (time A), at the last 
day of RT (time B), a median time of two months (time C) 
and seventeen months after RT (time D) using a validated 
questionnaire (Expanded Prostate Cancer Index Composite; 
comprising 50 items concerning urinary, bowel, sexual and 
hormonal domains). The multi-item scale scores were 
transformed lineary to a 0-100 scale, with higher scores 
representing better QoL. Baseline QoL assessment was 
available from 101 / 66 patients with / without a spacer. 
Responses to both the baseline and last (time D) 
questionnaire were available in 94 / 57 cases with / without 
a spacer. 
 
Results: Apart from higher prescription doses in the spacer 
group, baseline patient characteristics were well balanced 
between patients with vs. without a spacer (Table). In 
particular, baseline QoL was comparable. Acute toxicity 
(corresponding to QoL changes at times B and C relative to 
baseline levels) did not differ significantly, with only a 
tendency for better scores in the spacer group. However, 
mean bowel bother scores >1 year after RT in comparison to 
baseline did not change for patients with a spacer (mean 
change of 0 points) in contrast to patients without a spacer 
(mean decrease of 7 points). Long-term mean urinary bother 
scores did not decrease in both groups. At time D, 
statistically significant differences were found in the function 
items “bloody stools”, “painful bowel movements” and 
“frequency of bowel movements”. Focusing on patients with 
no problem with bowel symptoms initially, 0% vs. 12% with 
vs. without a spacer reported a moderate/big problem with 
bowel symptoms >1 year after RT (p<0.01). 
 
 
Conclusion: Though acute rectal symptoms are still reported, 
spacer injection is associated with a significant long-term 
benefit for patients after prostate cancer RT. 
 
PO-0739  
IMRT versus 3D conformal radiotherapy when used in 
combination with I-125 prostate brachytherapy 
A. Yorozu
1Tokyo Medical Centre- NHO, Department of Radiation 
Oncology, Tokyo, Japan 
1, T. Tanaka1, R. Kota1, Y. Takagawa1, Y. Shiraishi1, 
K. Toya1, S. Saito2 
2Tokyo Medical Centre- NHO, Department of Urology, Tokyo, 
Japan 
 
Purpose or Objective: To compare biochemical outcomes 
and toxicity of intensity modulated radiotherapy (IMRT) and 
three-dimensional conformal radiotherapy (3D-CRT) when 
used in combination with I-125 brachytherapy (BT) for the 
treatment of unfavorable-risk prostate cancer. 
 
Material and Methods: A retrospective review was performed 
on 839 patients with localized prostate cancer who received 
external-beam radiotherapy (EBRT) following BT between 
2003 and 2012. Patients were categorized into National 
Comprehensive Cancer Network risk groups: 616 were 
unfavorable intermediate-risk (Gleason score 4+3, or Gleason 
score 3+4 with positive biopsy core rate >1/3), and 223 were 
high-risk. Treatment begins with BT, followed 6 weeks later 
by 45 Gy/25 fractions of EBRT. EBRT was delivered via 3D-
CRT in 616 men at first and via IMRT technique for 223 men 
after 2010. The prescription dose for I-125 was 100 Gy, up to 
110 Gy after 2009. All patients underwent a CT scan for 
postplan dosimetry at day 30. The rectal volumes receiving 
doses higher than 30 Gy, 35 Gy, and 40Gy should be kept 
under 35%, 25%, and 15%, respectively. Neoadjuvant 
androgen deprivation therapy was given to 45% of patients. 
Biochemical failure was defined with the Phoenix criteria, 
and toxicity was graded according to the National Cancer 
Institute’s Common Terminology Criteria for Adverse Events, 
prospectively collected. The median (range) follow-up was 7 
(2-12) years for the entire cohort; 8.3 years for 3D-CRT, and 
4.3 years for IMRT. The biological effective dose (BED) was 
calculated using an α/β of 2 Gy and the D90 values of the 
prostate on a day-30 CT scan. Comparisons were made by 
chi-square test and log-rank test. 
 
Results: The total BED value of the prostate was higher in the 
IMRT group than in the 3D-CRT group (219 Gy2 vs. 209 Gy2, p 
<0.001). The 5-year actuarial freedom from biochemical 
failure for the IMRT group vs. the 3D-CRT group were 92.7% 
vs. 92.6% (p=0.825) for all; 95.4% vs. 95.1% for intermediate-
risk, and 88.0% vs. 84.8% for high-risk group (p=0.788), 
respectively. Acute gastrointestinal (GI) grade 2+ toxicities 
occurred in 0.5% of the IMRT group and 2.7% of the 3D-CRT 
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group (p =0.056), and the 5-year actuarial grade 2+ GI 
toxicity rate was lower in the IMRT group than in the 3D-CRT 
group (5.0% vs. 12.1%, p <0.01). A lower incidence of acute 
genitourinary (GU) grade 2+ toxicities occurred in the IMRT 
group than in the 3D-CRT group (7.1% vs. 16.4%, p = 0.001). 
The 5-year actuarial grade 2+ GU toxicity rate for the IMRT 
vs. the 3D-CRT group was 16.3% vs. 21.7% (p = 0.103), 
respectively. 
 
Conclusion: IMRT combined with I-125 brachytherapy in 
prostate cancer patients found a lower incidence of toxicities 
than 3D-CRT combination, without compromise of 
biochemical outcomes.  
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Purpose or Objective: Studies on extended or sentinel node 
(SN) pelvic lymph node dissection (PLND) have shown a higher 
detection rate compared to standard PLND in high risk 
prostate cancer (HRPC). In accordance with these findings, 
we previously demonstrated that ~30% of SNs in HRPC-
patients were detected outside of the radiotherapy volume 
for elective lymph node irradiation. The aim of this study was 
to assess efficacy of individually SN-guided pelvic intensity 
modulated radiotherapy (IMRT) by determining nodal 
clearance rate {(n expected nodal involvement – n observed 
regional recurrences)/ n expected nodal involvement} in 
comparison to surgically staged patients. 
 
Material and Methods: Data on 475 HRPC patients were 
examined. Sixty-one consecutive patients received pelvic SN-
based IMRT (5x1.8Gy/week to 50.4Gy (pelvic 
nodes+individual SN) and an integrated boost with 
5x2.0Gy/week to 70.0Gy to prostate + (base of) seminal 
vesicles) and neo-/adjuvant long-term androgen deprivation 
therapy; 414 patients after SN-PLND were used to calculate 
the expected nodal involvement rate for the radiotherapy 
sample. Biochemical control and overall survival (OS) were 
estimated for the SN-IMRT patients using the Kaplan-Meier 
method. The expected frequency of nodal involvement in the 
radiotherapy group was estimated by imputing frequencies of 
node-positive patients in the surgical sample to the pattern 
of Gleason, PSA, and T-category in the radiotherapy sample. 
 
Results: After a median follow-up of 61 months, five year OS 
after SN-guided IMRT reached 84.4%. Biochemical control 
according to the Phoenix definition was 73.8%. The nodal 
clearance rate of SN-IMRT reached 94%. The estimated nodal 
involvement in the SN-IMRT group was 28.6% (95%-CI:19.3%-
37.7%). Retrospective follow-up evaluation is the main 
limitation. 
 
Conclusion: Radiation treatment of pelvic nodes 
individualized by inclusion of SN is an effective regional 
treatment modality in HRPC patients. The pattern of relapse 
indicates that the SN-based target volume concept correctly 
covers individual pelvic nodes. Thus, this SN-based approach 
justifies further evaluation including current dose-escalation 
strategies to the prostate in a larger prospective series. 
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Purpose or Objective: Whether the benefit of androgen 
ablation therapy (AAT) remains currently unclear in the era 
of dose escalation and the recent radiation therapy oncology 
group trials regarding this issue are still under accrual. We 
tried to evaluate the role of long-term adjuvant AAT for more 
than 12 months after completion of high-dose intensity 
modulated radiotherapy (IMRT) for high-risk prostate cancer 
patients at the single institution retrospectively.  
 
Material and Methods: Between 2005 and 2013, there were 
177 high-risk patients treated with radical IMRT. From 2005 
to 2009, 25 patients were treated by LINAC-IMRT, and since 
2010, remaining 152 patients were treated by helical 
tomotherapy. High-risk was defined as having one or more 
among three factors such as pretreatment prostate specific 
antigen (pPSA) levels > 20 ng/ml, or Gleason score (GS) > 7, 
or clinical stage ≥ T3a. Ninety-four patients (53.1%) had pPSA 
levels > 20 ng/ml, and 91 patients (51.4%) had GS > 7. 
Clinical stage T3 or 4 was diagnosed in 143 patients (80.8%) 
and 21 (11.9%) had pelvic lymph node metastasis initially. 
Among all patients, 95.5% received neoadjuvant/concurrent 
and 91.1% had adjuvant AAT. Median fraction size was 2.2 Gy 
for prostate plus proximal seminal vesicles with 
simultaneously integrated boost during whole pelvic 
irradiation of 1.8 Gy fraction. Most patients (88.1%) received 
whole pelvic irradiation of a median of 45.0 Gy. Median total 
nominal dose was 72.6 Gy (66.0 ~ 78.0) which was equivalent 
to a median of 81.4 Gy α/β 1.5 (74.2 ~ 86.3) in biologically 
effective dose of 1.8 Gy fraction. Biochemical failure (BCF) 
was defined as nadir plus 2 ng/ml.  
 
Results: Follow-up period was ranged from 6 to 117 months 
(median: 37). Eighteen patients (10.2%) developed BCF and 5-
year BCF-free survival rate (BCFFS) was 83.1%. Six out of 18 
BCF patients eventually developed clinical failure and 5-year 
clinical failure-free survival (CFFS) was 93.7%. 5-year cause-
specific survival (CSS) and overall survival (OS) was 99.1% and 
95.8%, respectively. Several potential prognostic factors were 
analyzed for each survival endpoints by multivariate analysis. 
Whether adjuvant AAT or not (p=0.000) and N stage (p=0.016) 
were significant factors affecting BCFFS but no factors were 
significant for CFFS, CSS, or OS. Biologically effective dose 
according to 1.8 Gy (≤80.0 Gy α/β 1.5 vs. > 80.0 Gyα/β 1.5) 
was not a significant factor in all survival endpoints. There 
was only one patient who suffered urethral stricture of grade 
3 late toxicity. No patient suffered grade 3+ in 
gastrointestinal or grade 4+ in genitourinary late toxicity. s 2 
ng/ml.  
 
Conclusion: Based on BCF end point, even high-dose IMRT 
was an insufficient treatment for high-risk prostate cancer 
patients if adjuvant AAT was not added. The addition of 
adjuvant AAT significantly reduced the BCF, although longer 
follow-up is needed to determine if the combined treatment 
impacts significantly on other survivals 
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